Zipalertinib (CLN-081/TAS6417)
Relapsed EGFR exon 20 insertion NSCLC
Key Facts
About Cullinan Therapeutics
Cullinan Therapeutics is a public, clinical-stage biotech company driving forward a deliberate pipeline of innovative therapies in autoimmune diseases and oncology. The company's strategy centers on rigorous scientific decision-making and strategic risk-taking to accelerate promising molecules. Key near-term catalysts include initial clinical data for CLN-978 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Q2 2025, and the completion of a rolling NDA submission for zipalertinib in EGFR exon 20 insertion non-small cell lung cancer (NSCLC).
View full company profileAbout Cullinan Therapeutics
Cullinan Therapeutics is a public, clinical-stage biotech company driving forward a deliberate pipeline of innovative therapies in autoimmune diseases and oncology. The company's strategy centers on rigorous scientific decision-making and strategic risk-taking to accelerate promising molecules. Key near-term catalysts include initial clinical data for CLN-978 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Q2 2025, and the completion of a rolling NDA submission for zipalertinib in EGFR exon 20 insertion non-small cell lung cancer (NSCLC).
View full company profile